Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma.

Magi A, Masselli M, Sala C, Guerriero A, Laise P, Puccini B, Rigacci L, Breschi C, Crociani O, Pillozzi S, Arcangeli A.

Sci Rep. 2019 Jun 13;9(1):8586. doi: 10.1038/s41598-019-44661-x.

2.

Tissue-engineered aneurysm models for in vitro assessment of neurovascular devices.

Shen TW, Puccini B, Temnyk K, Herting S, Cardinal KO.

Neuroradiology. 2019 Jun;61(6):723-732. doi: 10.1007/s00234-019-02197-x. Epub 2019 Mar 27.

PMID:
30918991
3.

Role of Epstein-Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature.

Granai M, Ambrosio MR, Akarca A, Mundo L, Vergoni F, Santi R, Mancini V, di Stefano G, Amato T, Bellan C, Puccini B, Sorrentino E, Naresh KN, Leoncini L, Marafioti T, Lazzi S.

Haematologica. 2019 Jun;104(6):e269-e273. doi: 10.3324/haematol.2018.215053. Epub 2019 Mar 7. No abstract available.

4.

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.

Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network.

Br J Haematol. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8. No abstract available.

PMID:
30407625
5.

The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas.

Rigacci L, Kovalchuk S, Berti V, Puccini B, Mannelli L, Benelli G, Dini C, Pupi A, Bosi A.

World J Nucl Med. 2018 Jul-Sep;17(3):157-165. doi: 10.4103/wjnm.WJNM_42_17.

6.

Diffusion-Weighted and Perfusion-Weighted MRI to Evaluate Therapeutic Response in Lymphoma: A Comparison with FDG-PET/CT.

Calistri L, Puccini B, Berti V, Grazzini G, Nardi C, Rigacci L, Colagrande S.

Acta Haematol. 2018;139(2):74-76. doi: 10.1159/000485548. Epub 2018 Jan 26. No abstract available.

PMID:
29393082
7.

Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.

Cencini E, Puccini B, Rigacci L, Fabbri A, Kovalchuk S, Mannelli L, Benelli G, Carfagno T, Simontacchi G, Bocchia M, Bosi A.

Leuk Lymphoma. 2018 Jun;59(6):1420-1426. doi: 10.1080/10428194.2017.1387909. Epub 2017 Oct 10.

PMID:
28994343
8.

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.

9.

Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.

Puccini B, Nassi L, Minoia C, Volpetti S, Ciancia R, Riccomagno PC, Di Rocco A, Mulè A, Toldo C, Sassone MC, Guariglia R, Filì C, Finolezzi E, Falorio S, Zanon S, Furlan A, Doa G, Zaja F; Fondazione Italiana Linfomi Postgraduate Master course.

Ann Hematol. 2017 Jul;96(7):1147-1153. doi: 10.1007/s00277-017-2996-8. Epub 2017 Apr 28.

PMID:
28451805
10.

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.

Marcheselli L, Bari A, Anastasia A, Botto B, Puccini B, Dondi A, Carella AM, Alvarez I, Chiarenza A, Arcari A, Salvi F, Federico M.

Br J Haematol. 2015 May;169(4):544-51. doi: 10.1111/bjh.13332. Epub 2015 Mar 29.

PMID:
25817296
11.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

12.

The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.

Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, Martinelli G, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M.

Am J Hematol. 2015 Jan;90(1):56-61. doi: 10.1002/ajh.23872. Epub 2014 Nov 19.

13.

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).

Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M; Italian Lymphoma Foundation (FIL).

Leuk Lymphoma. 2015 Apr;56(4):921-6. doi: 10.3109/10428194.2014.953142. Epub 2014 Oct 9.

PMID:
25110825
14.

Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.

Rigacci L, Puccini B, Kovalchuk S, Fabbri E, Bonizzoni E, Perrone T, Bosi A.

Support Care Cancer. 2014 Sep;22(9):2557-61. doi: 10.1007/s00520-014-2237-9. Epub 2014 Apr 17.

15.

Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions.

Baldini S, Carrai V, Puccini B, Rigacci L, Alterini R, Bosi A.

Transfus Med. 2014 Apr;24(2):125-6. doi: 10.1111/tme.12106. Epub 2014 Feb 7. No abstract available.

PMID:
24720383
16.

Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.

Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M, Pimpinelli N; Gruppo Italiano Linfomi Cutanei (GILC).

Eur J Haematol. 2014 Aug;93(2):129-36. doi: 10.1111/ejh.12315. Epub 2014 Apr 4.

PMID:
24635751
17.

Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.

Nobili S, Napoli C, Puccini B, Landini I, Perrone G, Brugia M, Benelli G, Doria M, Martelli M, Finolezzi E, Di Rocco A, Del Fava E, Rigacci L, Di Lollo S, Bosi A, Mini E.

Leuk Lymphoma. 2014 Sep;55(9):2071-8. doi: 10.3109/10428194.2013.866665. Epub 2014 Feb 24.

PMID:
24289107
18.

Primary lymphoma of bone: outcome and role of surgery.

Scoccianti G, Rigacci L, Puccini B, Campanacci DA, Simontacchi G, Bosi A, Capanna R.

Int Orthop. 2013 Dec;37(12):2437-42. doi: 10.1007/s00264-013-2055-6. Epub 2013 Aug 24.

19.

Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.

Fabbri A, Cencini E, Rigacci L, Bartalucci G, Puccini B, Dottori R, Gozzetti A, Bosi A, Bocchia M.

Leuk Lymphoma. 2014 Apr;55(4):781-5. doi: 10.3109/10428194.2013.826354. Epub 2014 Jan 24.

PMID:
23876098
20.

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.

Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M.

Hematol Oncol. 2013 Dec;31(4):179-82. doi: 10.1002/hon.2036. Epub 2012 Oct 29.

PMID:
23108928
21.

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.

Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, Cesaretti M, Rossi A, Rigacci L, Gaidano G, Merli F, Spina M, Stelitano C, Hohaus S, Barbui A, Puccini B, Miranda EC, Guida A, Federico M.

Leuk Lymphoma. 2013 Jan;54(1):53-7. doi: 10.3109/10428194.2012.691482. Epub 2012 Sep 28.

PMID:
22712840
22.

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).

Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, Zaja F, Bongarzoni V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E.

Ann Hematol. 2012 Jul;91(7):1013-22. doi: 10.1007/s00277-012-1422-5. Epub 2012 Feb 15.

PMID:
22349722
23.

Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.

Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S, Ciceri F, Fanin R, Rambaldi A, Falda M, Milone G, Guidi S, Martelli MF, Mazza P, Oneto R, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Ann Hematol. 2012 Jun;91(6):931-9. doi: 10.1007/s00277-011-1395-9. Epub 2012 Jan 14.

PMID:
22245922
24.

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U.

Blood. 2012 Mar 1;119(9):2066-73. doi: 10.1182/blood-2011-06-359943. Epub 2012 Jan 10.

25.

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.

Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, Vaggelli L, Zanoni L, Argnani L, Baccarani M, Fanti S.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12. doi: 10.1007/s00259-011-1916-8. Epub 2011 Sep 6.

PMID:
21894546
26.

Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.

Rigacci L, Puccini B, Iovino L, Martelli M, Finolezzi E, DI Lollo S, Doria M, Bosi A.

J Chemother. 2011 Aug;23(4):227-31.

PMID:
21803701
27.

Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.

Rigacci L, Landi C, Caruso JP, Puccini B, Alterini R, Carrai V, Perrone T, Bosi A.

Leuk Res. 2012 Feb;36(2):182-5. doi: 10.1016/j.leukres.2011.06.025. Epub 2011 Jul 14.

28.

Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.

Rigacci L, Fabbri A, Puccini B, Chitarrelli I, Chiappella A, Vitolo U, Levis A, Lauria F, Bosi A.

Cancer. 2010 Oct 1;116(19):4573-9. doi: 10.1002/cncr.25216.

29.

Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas.

Rigacci L, Nassi L, Puccioni M, Mappa S, Polito E, Dal Pozzo S, Alterini R, Carrai V, Puccini B, Bosi A.

Ann Hematol. 2007 Aug;86(8):565-8. Epub 2007 May 5.

PMID:
17483948

Supplemental Content

Loading ...
Support Center